aTyr Pharma (ATYR) 10-Q2018 Q1 Quarterly report

Filed: 15 May 18, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Good

New words: aid, ASC, Australia, Australian, BCF, bifurcation, bind, Bulletin, buy, clause, decade, delegated, elucidate, embody, evasion, extracellular, family, feature, fueled, GMP, histidyl, host, identical, indexed, investor, iv, justify, learning, lien, lifespan, mandatorily, notification, Notwithstanding, official, offshore, panel, parallel, perfection, personal, prioritization, proceed, reclassification, Release, repatriated, shortly, stranded, streamline, strike, synthetase, tangible, taxation, thereunto, TJCA, Today, tRNA, unamortized, undersigned, urge, vesting, vi, workforce

Removed: AAV, abbreviated, Acceleron, acquired, add, adding, addressable, AG, age, Alexion, allege, amenable, amortization, antisense, attendant, biopharmaceutical, biosimilar, Brain, branding, burdensome, calendar, cancel, cancellation, capture, causal, Century, chance, characterized, charitable, chemical, children, choice, claiming, communication, complementary, conclusion, confirmed, conform, confusion, consisting, contest, contre, convenience, Conversely, counteract, creating, deducting, demanding, demonstrated, disagree, distinct, DMD, Domagrozumab, Duchenne, ease, Emflaza, endorsing, endpoint, Esbriet, evolved, examined, exhibit, exon, expansive, experimental, exploring, Facio, failed, falsely, fatigue, fever, FibroGen, field, Finally, focusing, Foundation, fourth, French, Fulcrum, functioning, Genethon, guide, homeostatic, Hospital, Idera, imbalance, immunology, improved, incidence, indeterminate, India, inhibit, Innovation, inspect, insufficiently, interchangeable, invasion, Italfarmaco, Johnson, Justice, Kingdom, leading, leaving, les, letter, literature, locally, mammalian, Marathon, mark, matured, measure, medication, membership, Milo, mistakenly, modality, moment, morbidity, mutation, Nationwide, NeuroGen, neuromuscular, nintedanib, Nobelpharma, Novogen, Ofev, oligonucleotide, oppose, orchestrate, outlining, partially, pathophysiology, people, persuade, Pfizer, phenomenon, physician, Physiocrine, pirfenidone, positive, posting, prepare, prevalence, productivity, promoting, Promotional, propose, PTC, pulmonary, rapidly, rash, Raynaud, receptive, reference, referencing, referendum, requesting, requirement, resistance, responded, responding, restitution, restore, Roche, Santhera, Sarepta, scrutinized, shorten, significance, skipping, space, Spine, sponsoring, statistical, Stelara, stem, steroid, stringent, subjecting, subset, substitute, sued, suffering, Summit, survive, swallowing, system, territory, transport, Ultragenyx, underappreciated, underwriting, unforeseen, unfunded, unspecified, vector, website, weight

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated ATYR transcripts

ATYR similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of aTyr Pharma, Inc. (the “Company”) for the period ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sanjay S. Shukla, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2018	/s/ Sanjay S. Shukla
	Sanjay S. Shukla, M.D., M.S.
	President and Chief Executive Officer

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.